MX2019001937A - Métodos de tratamiento de trastornos del desarrollo con biguanidas. - Google Patents
Métodos de tratamiento de trastornos del desarrollo con biguanidas.Info
- Publication number
- MX2019001937A MX2019001937A MX2019001937A MX2019001937A MX2019001937A MX 2019001937 A MX2019001937 A MX 2019001937A MX 2019001937 A MX2019001937 A MX 2019001937A MX 2019001937 A MX2019001937 A MX 2019001937A MX 2019001937 A MX2019001937 A MX 2019001937A
- Authority
- MX
- Mexico
- Prior art keywords
- syndrome
- disorder
- methods
- developmental disorders
- biguanides
- Prior art date
Links
- 208000012239 Developmental disease Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 229940123208 Biguanide Drugs 0.000 title abstract 2
- 150000004283 biguanides Chemical class 0.000 title 1
- 208000029560 autism spectrum disease Diseases 0.000 abstract 2
- 201000003415 fragile X-associated tremor/ataxia syndrome Diseases 0.000 abstract 2
- 206010052075 Acquired epileptic aphasia Diseases 0.000 abstract 1
- 208000009575 Angelman syndrome Diseases 0.000 abstract 1
- 208000036640 Asperger disease Diseases 0.000 abstract 1
- 201000006062 Asperger syndrome Diseases 0.000 abstract 1
- 206010003805 Autism Diseases 0.000 abstract 1
- 208000020706 Autistic disease Diseases 0.000 abstract 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 abstract 1
- 208000001914 Fragile X syndrome Diseases 0.000 abstract 1
- 201000005802 Landau-Kleffner Syndrome Diseases 0.000 abstract 1
- 208000012202 Pervasive developmental disease Diseases 0.000 abstract 1
- 201000010769 Prader-Willi syndrome Diseases 0.000 abstract 1
- 208000006289 Rett Syndrome Diseases 0.000 abstract 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 abstract 1
- 206010049644 Williams syndrome Diseases 0.000 abstract 1
- 229960004111 buformin Drugs 0.000 abstract 1
- XSEUMFJMFFMCIU-UHFFFAOYSA-N buformin Chemical compound CCCC\N=C(/N)N=C(N)N XSEUMFJMFFMCIU-UHFFFAOYSA-N 0.000 abstract 1
- 208000024825 childhood disintegrative disease Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 229960003105 metformin Drugs 0.000 abstract 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229960003243 phenformin Drugs 0.000 abstract 1
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
- C07C279/24—Y being a hetero atom
- C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662376488P | 2016-08-18 | 2016-08-18 | |
| PCT/US2017/047505 WO2018035408A1 (en) | 2016-08-18 | 2017-08-18 | Methods of treating developmental disorders with biguanides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019001937A true MX2019001937A (es) | 2019-10-02 |
Family
ID=61190982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019001937A MX2019001937A (es) | 2016-08-18 | 2017-08-18 | Métodos de tratamiento de trastornos del desarrollo con biguanidas. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10123979B2 (https=) |
| EP (1) | EP3484452A4 (https=) |
| JP (1) | JP2019524834A (https=) |
| KR (1) | KR20190039974A (https=) |
| CN (1) | CN109715144A (https=) |
| AU (1) | AU2017313823A1 (https=) |
| CA (1) | CA3033967A1 (https=) |
| MX (1) | MX2019001937A (https=) |
| WO (1) | WO2018035408A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014159247A1 (en) | 2013-03-14 | 2014-10-02 | University Of Florida Research Foundation, Inc. | Di-amino acid repeat-containing proteins associated with als |
| US10509045B2 (en) | 2015-05-29 | 2019-12-17 | University Of Florida Research Foundation, Incorporated | Methods for diagnosing Huntington's disease |
| US10940161B2 (en) | 2016-04-04 | 2021-03-09 | University Of Florida Research Foundation, Incorporated | Manipulation of EIF3 to modulate repeat associated non-ATG (RAN) translation |
| JP2019524834A (ja) | 2016-08-18 | 2019-09-05 | オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | ビグアナイド系による発達障害の治療方法 |
| WO2018195110A1 (en) * | 2017-04-17 | 2018-10-25 | University Of Florida Research Foundation, Incorporated | Regolation of ran translation by pkr and eif2a-p pathways |
| JP2020535448A (ja) | 2017-09-25 | 2020-12-03 | ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． | Ｒａｎタンパク質の検出のための免役アッセイ |
| US11903910B2 (en) | 2017-09-26 | 2024-02-20 | University Of Florida Research Foundation, Incorporated | Use of metformin and analogs thereof to reduce RAN protein levels in the treatment of neurological disorders |
| GB201912760D0 (en) * | 2019-09-05 | 2019-10-23 | Healx Ltd | Treatment |
| WO2021055880A1 (en) | 2019-09-20 | 2021-03-25 | University Of Florida Researchfoundation, Incorporated | Detection of antibodies against ran proteins from serum and tissue lysates |
| GB202008699D0 (en) * | 2020-06-09 | 2020-07-22 | Healx Ltd | Treatment |
| CN113318111B (zh) * | 2021-06-21 | 2026-02-03 | 浙江大学 | Nav1.1激动剂在制备治疗自闭症的药物中的应用 |
| WO2023102111A1 (en) * | 2021-12-01 | 2023-06-08 | University Of Florida Research Foundation, Incorporated | Small molecule inhibitors of repeat associated non-aug (ran) translation and combination therapies |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6099859A (en) * | 1998-03-20 | 2000-08-08 | Andrx Pharmaceuticals, Inc. | Controlled release oral tablet having a unitary core |
| AU2003261298A1 (en) * | 2002-08-02 | 2004-02-23 | Penwest Pharmaceuticals Company | Sustained release formulations of metformin |
| US20060147947A1 (en) * | 2002-12-04 | 2006-07-06 | Javier Apfeld | AMPK pathway components |
| US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
| WO2008097861A2 (en) * | 2007-02-02 | 2008-08-14 | Braincells, Inc. | MODULATION OF NEUROGENESIS WITH BIGUANIDES AND GSK3-ß AGENTS |
| CN102058888B (zh) * | 2009-05-01 | 2014-06-11 | 常州高新技术产业开发区三维工业技术研究所有限公司 | 一种治疗能量代谢异常的药物组合物和其应用 |
| EP2653158B1 (en) * | 2010-12-13 | 2017-07-05 | Fukuoka University | Therapeutic agent for blood-brain barrier disruption syndrome |
| EP3013371A4 (en) * | 2013-06-26 | 2017-04-26 | Rett Syndrome Research Trust | Rett syndrome and treatments therefore |
| JP2019524834A (ja) | 2016-08-18 | 2019-09-05 | オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | ビグアナイド系による発達障害の治療方法 |
-
2017
- 2017-08-18 JP JP2019508879A patent/JP2019524834A/ja active Pending
- 2017-08-18 WO PCT/US2017/047505 patent/WO2018035408A1/en not_active Ceased
- 2017-08-18 CA CA3033967A patent/CA3033967A1/en not_active Abandoned
- 2017-08-18 AU AU2017313823A patent/AU2017313823A1/en not_active Abandoned
- 2017-08-18 CN CN201780057960.3A patent/CN109715144A/zh active Pending
- 2017-08-18 MX MX2019001937A patent/MX2019001937A/es unknown
- 2017-08-18 EP EP17842173.1A patent/EP3484452A4/en not_active Withdrawn
- 2017-08-18 KR KR1020197006647A patent/KR20190039974A/ko not_active Ceased
- 2017-08-18 US US15/680,417 patent/US10123979B2/en active Active
-
2018
- 2018-10-11 US US16/157,653 patent/US10426746B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20190046480A1 (en) | 2019-02-14 |
| EP3484452A1 (en) | 2019-05-22 |
| AU2017313823A1 (en) | 2019-02-28 |
| KR20190039974A (ko) | 2019-04-16 |
| US20180050001A1 (en) | 2018-02-22 |
| EP3484452A4 (en) | 2020-04-01 |
| US10426746B2 (en) | 2019-10-01 |
| CA3033967A1 (en) | 2018-02-22 |
| CN109715144A (zh) | 2019-05-03 |
| US10123979B2 (en) | 2018-11-13 |
| WO2018035408A1 (en) | 2018-02-22 |
| JP2019524834A (ja) | 2019-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019001937A (es) | Métodos de tratamiento de trastornos del desarrollo con biguanidas. | |
| MX2022004734A (es) | Metodos para tratar trastornos del desarrollo con gaboxadol. | |
| WO2021217004A3 (en) | Methods and compositions for treating virus-associated inflammation | |
| WO2016200101A3 (ko) | 트리사이클릭 유도체 화합물, 이의 제조방법 및 이를 포함하는 약학적 조성물 | |
| WO2018226758A3 (en) | METHODS FOR ENHANCED PRODUCTION AND ISOLATION OF CELL ORIGIN VESICLES AND TREATMENT OF INFLAMMATION AND NEUROLOGICAL DAMAGE | |
| WO2015067715A3 (en) | Gip-glp-1 dual agonist compounds and methods | |
| WO2018004283A3 (ko) | 글루카곤 유도체, 이의 결합체, 및 이를 포함하는 조성물, 및 이의 치료적 용도 | |
| UY36275A (es) | Compuestos aminopirimidinilo | |
| EA201491819A1 (ru) | Фармацевтические композиции для комбинированного лечения | |
| WO2016172496A8 (en) | Lsd1 inhibitors and uses thereof | |
| NZ748016A (en) | Use of cannabidiolic acid in the treatment of autism spectrum disorder and associated disorders | |
| WO2018224689A3 (en) | SOLID COMPOSITIONS FOR ORAL ADMINISTRATION | |
| AR093705A1 (es) | Depsipeptido y sus usos | |
| ECSP17044282A (es) | Formulación de relación fija de insulina glargina/lixisenatida | |
| MX2020012989A (es) | Agente terapeutico para la fibrosis. | |
| WO2015104658A3 (en) | Amorphous solid dispersion of dapagliflozin and process for the preparation of amorphous dapagliflozin | |
| MX2021005740A (es) | Novedoso compuesto como inhibidor de proteina quinasa, y composicion farmaceutica que comprende el mismo. | |
| MX2020013290A (es) | Uso del acido (s)-3-amino-4-(difluorometilenil) ciclopent-1-eno-1-carboxilico y compuestos relacionados, acido (1s,3s)-3-amino-4-(difluorometilideno) ciclopentano-1-carboxilico y vigabatrina en el tratamiento de trastornos del desarrollo. | |
| MY200499A (en) | Sulfonamide pharmaceutical composition | |
| CO2017008426A2 (es) | Ácido (2r,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-2-hidroxi-4- [(5-metiloxazol-2-carbonil)amino]pentanoico | |
| WO2017184670A3 (en) | Methods for treating zika virus infections | |
| EA201890744A1 (ru) | Фармацевтическая композиция, содержащая 8-[(3r)-3-амино-1-пиперидинил]-7-(2-бутин-1-ил)-3,7-дигидро-3-метил-1-[(4-метил-2-хиназолинил)метил]-1h-пурин-2,6-дион или его фармацевтически приемлемую соль | |
| MX362905B (es) | Tratamiento de combinacion. | |
| WO2018060962A3 (en) | Metformin amino acid compounds and methods of using the same | |
| WO2016163818A3 (ko) | 2-메톡시-4-(3-(4-메톡시페닐)프로필-1-엔-1-일)페놀을 유효성분으로 함유하는 염증성 질환 또는 관절염 치료 또는 예방용 약학적 조성물 |